A B S T R A C T To obviate several problems inherent in indirect thyroid-stimulating hormone (TSH) receptor antibody assays, we developed an enzyme-linked immunosorbent assay (ELISA) that measures antibodies binding to guinea pig fat cell membrane, which contain high concentrations of TSH receptors. Solubilized guinea pig fat cell membranes were adsorbed to plastic microtiter plates and served as the solidphase antigen. Test sera and affinity-purified alkaline phosphatase-conjugated anti-human IgG were co-incubated with membranes, after which p-nitrophenyl phosphate was added. Results were read when a positive control reached a standard color change (OD405nm). Received for publication 16 March 1983 and in revised form 17 June 1983. untreated Graves' patients had OD values at least 2 SD above the normal mean (Grave's mean±SD; 0.46±0.33, P < 0.001) and in each case 10-6 M TSH inhibited the binding by at least 60%, suggesting that the immunoglobulins were directed at the TSH receptor. Seven of 25 serum samples from patients with Hashimoto's disease, seven of 23 serum samples from patients with transient hyperthyroidism (subacute thyroiditis or painless thyrotoxic thyroiditis), and two of 10 samples from patients with thyroid carcinoma had significant elevations in the titers of membrane-directed immunoglobulins. Graves' patients who were treated with ablative therapy at least 6 mo earlier and who were euthyroid when restudied continued to have abnormally elevated membrane-directed immunoglobulins in six of eight samples studied. Further studies involved the substitution of affinity-purified alkaline phosphatase anti-IgM antisera for the anti-IgG antisera routinely used. Seven of 12 serum samples from patients with Graves' disease had significant elevations in binding which in every instance was inhibited by >60% by 10-6 M TSH.
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In sum, the present results indicate that (a) we have developed a sensitive, specific, reproducible, convenient ELISA for the measurement both of the total amount of circulating membrane-directed antibodies and of TSH-displaceable membrane-directed immunoglobulins. (b) This ELISA detected significant elevations in TSH-displaceable guinea pig membrane binding in 23 of 25 
INTRODUCTION
Graves' disease is associated with the production and circulation of heterogenous antibodies, some of which are directed against thyroid-stimulating hormone (TSH)' receptors located in thyroid gland membranes (1) (2) (3) (4) (5) (6) (7) (8) (9) . Recent investigations have proposed that a subset of these antibodies may bind to certain epitopes on TSH receptors and cause unabated stimulation, thereby resulting in thyroid hyperplasia and hypersecretion, the end result of which is detected as an elevated serum 3,5,3',5'-tetraiodothyronine (T4) and 3,5,3'-triiodothyronine (T3) and clinical thyrotoxicosis (1) (2) (3) (4) (5) (6) (7) (8) (9) .
Currently, most assays developed to detect these heterogenous antibodies measure either the inhibition of '251-TSH binding or the stimulation of thyroidal adenylate cyclase (1) (2) (3) (4) (5) (6) (7) (8) (9) . Studies measuring inhibition of 1251-TSH binding to thyroid gland membranes have greatly advanced our understanding of the pathophysiology of Graves' disease (1-3, 5, 6, 8, 9) , but suffer, in general, from several major disadvantages: (a) They require fractionation of serum with extraction of the immunoglobulins; (b) '25I-TSH binding inhibition represents an indirect method of assessing receptor-antibody interactions and it is not certain that direct binding assays would result in comparable findings; (c) '251-labeled bovine TSH is routinely used rather than a system that directly assesses the relationship between human TSH and its receptor; and (d) these assays, which frequently use protein A-Sepharose columns for serum fractionation, would detect immunoglobulins of only some IgG subclasses and would probably not determine whether other classes (e.g., IgM) play an important role in the receptor-immunoglobulin interactions in Graves' disease.
To study directly the binding of immunoglobulins ' Preparation of '25I-bovine TSH. The chloramine T method of iodination was used as published previously (11) . The specific activities of these preparations were -45-60
MCi/Mg. Aliquots were maintained at 4°C until used within 2-3 wk.
Preparation of IgG fractions. IgG fractions were prepared by separation of whole serum on columns of Protein-A-sepharose Cl-4B by methods previously reported (9, 12, 13) . IgG fractions prepared in this manner were subdivided into aliquots and kept frozen at -70°C until used.
Human thyroid membrane (HTM) preparations. Human thyroid glands were obtained from Graves' patients undergoing thyroidectomy, each of whom had given prior informed consent. The thyroid glands were frozen at -70°C within 30 min of their removal. On a separate day, the glands were thawed and membranes were prepared as described previously (9, (12) (13) (14) . In brief, minced thyroid gland in icecold 1 (14) .
Guinea Pig Fat Cell Membrane (GPF) Preparation. GPF containing TSH receptors were prepared by the method of Endo et al. (12) . In brief, epididymal and subcutaneous fat was obtained from 10 guinea pigs. This fat tissue ('100-200 g) was diluted 10-fold (wt/vol) and then minced and homogenized in a polytron homogenizer for 4 s at setting 6 in 20 mM Tris-HCl buffer, pH 7.45. The homogenate formed was filtered through cheesecloth (two layers) and then was centrifuged at 500 g at 4°C for 5 min. The resulting supernatant was filtered again through cheesecloth and centrifuged at 15,000 g at 4°C for 15 min; the pellet was washed and resuspended in 200 Ml of 20 mM Tris-HCI, pH 7.4, at a final concentration of -3 mg protein, an aliquot of which was further processed to obtain solubilized receptor as described (14) . Briefly, the receptor preparation pellet just obtained was solubilized with 0.1 M lithium 3,5-diiodosalicylate (2 ml/10 mg membrane protein) in 20 mM NaHCO3, pH 9.4. This mixture was homogenized for 3 s with a polytron at a setting of 6 and then incubated 1 h at room temperature and centrifuged at 38,000 g for 30 min. The supernatant was dialyzed at 4°C for 18 h against 20 mM NaHCO3, pH 9.4, and stored at -70°C in aliquots containing concentrations of -250 Mg/100 ,ul. The yield of membrane protein was -1-3 mg/g of wet weight of fat. Further dilutions were prepared as appropriate before use in the ELISA.
EMBA. Sera were assayed for membrane binding activity by a modified ELISA technique (10) . 100 Il (-2 Ag protein) of solubilized membrane was placed in flat bottomed, polystyrene microtiter plates in 10 mM phosphate and 150 mM NaCl buffer (PBS), pH 7.2, and allowed to incubate overnight at 4°C. The plates were then washed three times with PBS (pH 7.2) and filled with 100 MlA of 1% human serum albumin in PBS and incubated for 1 h at 37°C. This washing and blocking procedure with 1% albumin solution was performed to decrease nonspecific binding. The plates were then washed three times with PBS, pH 7.2, containing 0.1% human serum albumin and 0.05% Tween 20 (PBS-T). 100 Ml sera (diluted 1:5 with PBS-T) was added to each well and the plates were incubated for 1 h at 37°C and washed three times with PBS-T; 100 Ml affinity-purified alkaline phosphatase-conjugated anti-human IgG diluted 1:1,000 with PBS-T was then added to each well and incubated for 1 h at 370C. After three final washes with PBS-T, 150 Al of a solution of p-nitrophenyl phosphate (1 mg/ml) in diethanolamine buffer, pH 9.8, 0.01 M MgCl2 was incubated in each well until a standard serum reached an OD405nm of 1.10, as read by an automated spectrophotometer (Dynatech Laboratories, Inc.). In selected experiments anti-human IgM or IgA was substituted for anti-human IgG. All sera were assayed in duplicate and values are expressed as average
OD405nm. An aliquot of a single high-titer patient's serum was used as a standard throughout the study. The inter-and intraassay coefficients of variation of a given sample were <10%. Each plate always contained control wells to include (a) antibody conjugate alone, (b) normal sera plus antibody conjugate without membrane, and(c) membrane plus antibody conjugate. In all cases, these controls read <0.05 OD units. All samples and controls were analyzed in duplicate and expressed as the mean optical density of each sample.
ELISA (EMBA) competitive binding studies. Competitive binding studies were conducted by the same techniques as the binding assay (see above), with the following modifications. Agents to be studied as competitors for putative TSH receptor binding were diluted to appropriate concentrations in PBS-T. This solution was used to dilute test sera, which then were incubated in the membrane-coated plates for 1 h at 37°C. The assay was otherwise performed in the routine manner. Results were expressed as average optical density units of duplicate samples.
Drug interactions with membrane binding activity. Several sera with high specific binding activity were used to test the in vitro effect of drugs by two techniques: (a) They were performed in the same manner as the blocking studies, mak-ing appropriate dilutions of the drugs in PBS-T and co-incubating all reagents (drugs, sera, and membranes) simultaneously. (b) Preincubation of drug and membrane were performed in the plates for 1 h at 370C; after washing with PBS-T, sera were then added and the assay was completed in the routine mariner. Results are expressed as percentage change from control OD reading.
Column fractionation of HTM and antigenic analysis. To determine whether solubilized HTM preparations could also be used as the solid phase for the assay of TSH receptor specific antibodies, we sought to evaluate the possibility that such preparations contained other antigens, such as microsomes or thyroglobulin, to which antibodies might be found in patients' sera. Thus, 1 mg solubilized HTM was passed over a G100 Sephadex column (0.9 X 60 cm) equilibrated in Tris-NaCl and 30 1-ml sequential fractions were collected over a 90-min period. This column had been calibrated with ribonuclease (mol wt 13,700), chymotrypsinogen A (mol wt 25,000), BSA (mol wt 67,000), and aldolase (mol wt 158,000).
Three microtiter plates were prepared; each plate contained 100 ,d from each of the 30 fractions (in duplicate) as well as duplicate samples of crude HTM diluted 1:100 in PBS and crude GPF diluted 1:100 in PBS. These plates were incubated overnight at 4°C and washed three times in PBS-T. To one plate, 100 pg of rabbit anti-human thyroglobulin antisera (thyroglobulin antibody test, Ames Co., Miles Laboratories Inc., Research Products Div., Elkhart, IN) diluted 1:100 with PBS-T was added to each well. To the second plate, a similar dilution of rabbit antimicrosomal antisera (thyroid microsomal antibody test, Ames Co.) was added. To the third plate, human sera with high-titer anti-TSH receptor antibody diluted 1:100 was added. All the plates were washed with PBS-T and to the first two plates affinity-purified alkaline phosphatase-conjugated anti-rabbit IgG (Miles Yeda Laboratories, Rehovot, Israel) diluted 1:1,000 with PBS-T was added. To the third, the affinity-purified antihuman IgG used in the routine ELISA assay was added. The plates were incubated 1 h at 37'C, then washed three times with PBS-T. 150 pI p-nitrophenyl phosphate (1 mg/ml) was added to the plates and after incubation at room temperature for 20 min, the optical density readings were determined.
IgA and IgM class studies. To determine whether there was significant TSH receptor binding by immunoglobulin of classes other than IgG, EMBA were conducted with affinity-purified alkaline phoshatase-labeled anti-IgA and antiIgM antisera diluted 1:1,000. Results were compared with a group of normal controls analyzed at the same time.
Statistical analysis. Unpaired t tests were used to determine whether values were different in two comparison populations, and paired t tests were used when TSH receptor directed immunoglobulins were analyzed over time in a single patient (15) .
RESULTS
Preliminary studies on membrane antigens. The preliminary study to determine the suitability of HTM as antigen substrate revealed binding of antithyroglobulin and antimicrosomal specific antisera in fractions corresponding to a mol wt >67,000. This binding was >100-fold increased over background. These same fractions also showed activity when incubated with Graves' patient's sera. These results were interpreted as indicating that antigenic thyroglobulin and thyroid microsomes were present in the solubilized HTM fraction, thus making it unsuitable for assaying specifically for Graves' specific IgG. GPF did not show any specific binding to antithyroglobulin or antimicrosomal antibodies and thus was used in the assay throughout the study.
Reaction Other inhibitors. Equimolar (10-6 M) concentrations of alpha subunit and ,BTSH and high molar concentrations of insulin, and HCG did not possess the ability to inhibit the membrane binding (Fig. 3) (Table I) . Only propylthiouracil (PTU) had an effect on binding in physiologic concentrations of 5 X 10' M. 8-Anilino-l-naphthalene sulfonic acid (ANS) and beta mercaptoethanol both inhibited binding (by -50% at 5 X 10-4 M), probably because of a direct effect upon either circulating immunoglobulins or the receptor itself. Dithiothreitol (DTT) caused inhibition only when premixed with the immunoglobulin, and was thus thought to exert its effect by disrupting the structure of the immunoglobulin, rather than by directly interfering with receptor binding. Propranolol, methimazole, dexamethasone, oxidized glutathione, and methiamide had no treated patients were restudied when they were euthyroid, the highest sample decreased from 0.3 to 0.28 and the remaining five pretreatment borderline elevated samples did not generally change greatly as the posttreatment range for these five samples was 0.100 to 0.220, mean 0.16±0.06 (NS). IgM and IgA studies. 12 Graves' patients sera and 20 sera from normal subjects were analyzed with affinity-purified alkaline phosphatase-conjugated goat anti-human 1gM or IgA antiserum, instead of IgG antisera. When either the IgA or IgM antiserum was incubated with membrane alone or patients serum alone (Graves' and normals) the optical density reading was <0.05. Furthermore, this IgM antiserum was shown not to cross-react with IgG in whole serum or IgG after fractionation on columns of Protein-A-Sepharose CL-4B. All normal and Graves' patients sera had optical density readings less than controls when IgA antiserum was used, suggesting they did not have immunoglobulins of the IgA class (Fig. 5 ) directed against GPF. In contrast, when the IgM antiserum was used, the mean reading of the Graves' sera (0.43±0.24) was significantly higher (P < 0.05) than that of 0.23±0.07 noted in normal patients' sera, suggesting the presence of membrane binding antibodies. Further, seven of seven positive Graves' sera tested with anti IgM had >60% suppression by TSH, suggesting that these circulating membrane-directed immunoglobulins were directed specifically at or near the TSH receptor (Fig. 6) .
DISCUSSION
We developed a rapid ELISA capable of detecting circulating GPF antibodies (putative TSH receptor antibodies) in dilutions of whole serum. This assay can be easily performed within one working day and has the further advantages that isotope is not required and that direct interactions of the circulating antibodies with the putative TSH receptor are assessed. This ELISA has inherent advantages over the '25I-TSH binding assays used to date (1-3, 5, 6, 8, 9 ). '25I-TSH binding assays require the preparation of IgG fractions from sera, generally performed with protein A-Sepharose C1-4B columns. These column procedures are quite time consuming and usually only about five to 10 samples can be processed daily. In contrast to the more difficult 1251-TSH binding assay, the ELISA assay presented herein is sensitive enough to detect circulating antibodies in 23 of 25 untreated Graves' patients. In the majority of reports with the 125I-TSH binding assay, it has been noted to be positive in only -70-80% of Graves' patients (5, (16) (17) (18) (19) , although two recent studies have indicated this percentage to be 86% (8) and 94% (9). Borges et al. (9) modified the 125I-TSH binding inhibition assay so that whole serum could be analyzed; '251-bovine TSH binding was 86.3±7% with control normal serum samples and decreased to 61±15% in serum from Graves' disease patients. There was, however, considerable overlap between the two sets of samples as the normal serum samples ranged from 74 to 104% of serum-free controls. These authors report (9) that 27 of 35 samples (77%) from Graves' disease patients were > 2 S.D. below the mean average in normals.
The in vitro studies reported here demonstrated that the ELISA described is relatively specific, as only TSH (and thyroglobulin) displaced antibody binding, whereas the alpha TSH subunit, f, subunit, insulin, HCG, and albumin did not interact. This inhibition was not observed in most antisera that were thought to be against antigens on the GPF not involved with TSH binding. Thyroglobulin has previously been noted to inhibit 125I-TSH binding to TSH receptors (16) . The pathophysiologic meaning of this thyroglobulin interaction is unknown. We have also performed various in vitro studies directly assessing whether various agents influenced immunoglobulin-membrane binding. We observed that 5 X 10' M PTU decreased the binding of serum immunoglobulin to the TSH receptor. This level of PTU is higher that that observed in serum (17) , but may be comparable to that achieved intrathyroidally. Our results suggesting that PTU may inhibit immunoglobulin binding to TSH receptors on membranes represents another mechanism involving immunoglobulin formation or action by which PTU Guinea Pig Membrane-binding Immunoglobulins (Subclasses 1, 2, 4) , but it may also react with other Ig classes (25, 26) ; thus, this assay does not define the subclass to which these circulating antiimmunoglobulins belong. Finally, because TSH displacement was not performed, it is not possible to ascertain whether their '251-Staphylococcus Protein A binding assay detects receptor-directed immunoglobulins. The ELISA described herein confirms the findings of a high frequency of circulating immunoglobulins directed against GPF in autoimmune diseases (24) . Approximately 30% of serum samples from patients with Hashimoto's disease, painless thyrotoxic thyroiditis, or subacute thyroiditis had TSHdisplaceable immunoglobuins; in contrast, only 20% or less of serum samples from patients with thyroid carcinoma or a variety of rheumatic or collagen diseases had TSH-displaceable immunoglobulin binding. We interpret these findings to indicate that most membrane binding antibodies in autoimmune diseases are directed against antigens separate from the TSH receptors. The '20% that were TSH displaceable may represent antibodies against determinants near or part of the TSH receptor itself. However, they may be different from the antigenic determinants in the receptor responsible for thyroid stimulation in Graves' disease, as these autoimmune patients had no evidence of hyperthyroidism. We also confirmed the presence of TSH-displaceable antibodies in some normal patients. We do not understand why normal subjects appear to possess these antibodies (in a slightly higher frequency than expected by statistical definition, i.e., 2.5% of the normal population), but we were intrigued to find that several of the euthyroid individuals with such antibodies had a positive family history for autoimmune thyroid disease. Perhaps the EMBA assay is detecting antibodies that antedate the initiation of clinical disease. Alternatively, it is possible that even normal individuals produce these TSH receptor antibodies, as Brown et al. (27) have recently suggested. At present, we are not certain whether these membrane-directed TSH-displaceable immunoglobulins have any physiologic implications. It has been postulated that in normal subjects these antibodies could be present as part of the normal homeostatic regulation of receptor production and/or disposal (28, 29 (7, 16, (30) (31) (32) indicating that after several months the levels of these immunoglobulins were restored to normal in this circumstance. Although we are uncertain why our results differ, we speculate that it could be related to the fact that our assay is more sensitive or, perhaps, is measuring a different population of circulating antibodies. In this regard, it should be emphasized we are measuring putative receptor binding, not glandular stimulation. However, our results are consistent with the recent findings by How et al. (33) that nine of 18 patients who had thyrotoxic Graves' disease (treated with PTU) 2 yr earlier were still sensitized to thyroid antigen and continued to demonstrate a suppressor-cell abnormality, even though they were clinically and biochemically euthyroid. Moreover, Wood and Ingbar (34) reported that, when 15 patients with Graves' disease who had PTU-induced remission were studied -25 yr later, approximately nine had a demonstrable abnormality in thyroid hormone homeostasis. The types of abnormalities generally indicated hypothyroidism with a subnormal T4 response to exogenous TSH administration, abnormal perchlorate discharge test and the presence of antimicrosomal antibodies (and recurrent thyrotoxicosis in one), supporting the concept that Graves' disease is an autoimmune process that is progressive over time and theoretically could be associated in some patients with persistent detectable levels of TSH receptor-directed immunoglobulins. Furthermore, it is consistent with present theories of immunoglobulin regulation that treatment modalities directed at the thyroid gland might not be expected to affect the production of immunoglobulins (1), especially if the putative antigenic stimulus (i.e., TSH receptor) was physically still present.
Perhaps the most interesting data in this paper relate to the possibility that there are membrane-directed circulating IgM class immunoglobulins that may be receptor specific. Several recent studies have indicated that the levels of TSH receptor-directed immunoglobulins appear to be directly proportional to the IgG concentration and that it is considered likely that IgG immunoglobulins account for most of the antireceptor activity (35) (36) (37) (38) . The presence of several different classes of antibody against the receptor may also have implications concerning the immunoregulatory derangement involved in the production of autoantibodies and the immunoglobulins gene rearrangement involved in autoantibody production (39, 40) .
Thus, in summary, the ELISA reported seems to be a very useful tool, which will allow the sensitive and tapid measurement of TSH-displaceable, membranebinding immunoglobulins and may prove useful in a variety of investigative studies. It may prove helpful in predicting the likelihood of relapse in Graves' disease or could aide in the diagnosis of autoimmune thyroid disease either in the routine case of thyrotoxicosis or in the more unusual case of a patient with euthyroid ophthalmopathy (7, 9, (41) (42) (43) . Indeed, in contrast to previously reported assays (42) , this ELISA appears to meet the requirements of simplicity, rapidity, and sensitivity which are essential for extensive clinical application. However, it should be emphasized that this assay measures only binding immunoglobulins and that it is not known, at present, what relation these immunoglobulins have to the stimulation or inhibition of thyroidal synthesis and/or secretion.
